In infected cattle, bovine herpesvirus type 4 (BHV-4) induces an immune response with low neutralizing antibody levels or in the absence of such antibodies. For the study of this phenomenon, monoclonal antibodies (MAbs) raised against two BHV-4 glycoproteins identified previously (150K/120K/51K and 120K/16-5K) were used in neutralization tests. None of the MAbs except for MAb 16 could neutralize alone; pairs of MAbs against the 150K/120K/51K and 120K/16-5K glycoproteins were able to neutralize BHV-4 infectivity. MAbs involved in neutralization were used in competitive binding assays to identify epitopes relevant for BHV-4 neutralization. These MAbs showed a low avidity and a weak neutralizing activity, and they partially decreased BHV-4 attachment to cells. These results suggest that the BHV-4 glycoprotein domains involved in viral infectivity are poorly exposed to the immune system.
Introduction
Bovine herpesvirus type 4 (BHV-4) has been isolated from cattle showing various clinical symptoms (ocular, respiratory and genital involvements, skin lesions, malignant catarrhal fever and enteric diseases) or from healthy cattle (reviewed by Thiry et al., 1989) . The humoral immune response of cattle to BHV-4 infection is characterized by low neutralizing antibody levels or an absence of such antibodies (reviewed by Thiry et al., 1989) . In a previous experiment on cattle, complement was shown to increase the neutralizing activity of sera from convalescent animals (Dubuisson et al., 1987) . In another experiment a secondary antibody response, measured by immunofluorescence, appeared after dexamethasone treatment of latently infected cattle but this anamnestic response had no neutralizing activity, which suggests that only early immunoglobulins are involved in neutralization (Dubuisson et aL, 1989c) .
The neutralization of virus infectivity by antibodies, directly or indirectly, has been proposed as a major mechanism of immunological defence against virus invasion (Dimmock, 1984 (Dimmock, , 1987 McCullough, 1986) . Several mechanisms of neutralization have been described. They affect early events of virus infection such as virus binding to specific cell surface receptors, virus entry and virus uncoating (reviewed by Dimmock, 1984 Dimmock, , 1987 Iorio, 1988) . Different monoclonal antibodies (MAbs) of more than one specificity may be required for 0000-9186 © 1990 SGM complete neutralization of a population of viral particles (Iorio & Bratt, 1984) . Moreover, other data suggest not only a requirement for more than one type of antibody molecule but synergistic enhancement of neutralization by pairs of antibodies to different antigenic sites (Volk et al., 1982; Kingsford, 1984) .
Twenty-nine BHV-4 structural proteins have been identified previously by SDS-PAGE of purified labelled virus, 10 of them being glycosylated. Two major glycoproteins were identified by anti-BHV-4 MAbs (Dubuisson et al., 1989b) . The first is a complex of three glycopolypeptides (150K/120K/51K) and the second is made up of another 120K glycopolypeptide linked to a 16.5K non-glycosylated polypeptide.
In order to understand the weakness or absence of BHV-4 neutralizing activity observed in sera from infected animals, we performed various neutralization tests with MAbs raised against the two major glycoproteins described previously (Dubuisson et al., 1989b) , and we identified epitopes involved in neutralization by competitive binding assays.
Methods
Cells and virus. The V Test strain of BHV-4 used in this work was isolated from a case of orchitis (Thiry et al., 1981) and plaque-purified three times. Virus was propagated on Georgia bovine kidney (GBK) cells and Madin Darby bovine kidney (MDBK) cells (ATCC-CCL22) grown in MEM supplemented with 5% newborn calf serum (Gibco). Each virus used in these experiments was at passage 14 or 15.
Monoclonal antibodies. Production of hybridomas and characterization of MAbs by immunoprecipitation and Western blotting were as described previously (Dubuisson et al., 1989a, b) . Other hybridomas were produced following a single-hit intrasplenic immunization 4 days before fusion, according to Spitz (1986) . MAbs used in neutralization tests were purified by ammonium sulphate precipitation from ascites fluids obtained from BALB/c mice bearing intraperitoneal hybridomas. MAbs used in competition tests were purified on Protein ASepharose CL-4B (Pharmacia) according to Ey et al. (1978) as modified by Sepp~lii et al. ( 1981 ) . A fraction of Protein A-purified antibodies was biotinylated (Goding, 1980) . Briefly, the purified IgGs were dialysed overnight against carbonate buffer (0.1 M, pH 8). N-hydroxysuccinimidobiotin (Sigma), dissolved in DMSO at a concentration of 1 mg/ml, was added at a ratio of 0.2 nag of biotin derivative to 1 mg of IgG, and the reaction was allowed to proceed for 4 h at room temperature. To remove free biotin, the mixture was dialysed against phosphatebuffered saline (0.15 t,i-NaC1, 2.9 mM-KC1, 8.9 mM-NazHPO4, 1"6 mM-KH2PO4 pH 7.2; PBS).
Antisera. The 150K/120K/51K complex was purified on Protein ASepharose CL-4B (Pharmacia) as described for immunoprecipitation except that serum anti-mouse immunoglobulins were omitted. Then, this protein was injected intradermally into a rabbit according to the method described by Israel et al. (1988) . Convalescent serum collected from a bull at day 32 after infection was used as the polyvalent antiserum.
Neutralization tests. MAbs alone or pairs of MAbs (1 : 1) were used in neutralization tests. Fifty ttl of MAbs (25 ~tg of each MAb) was mixed with 25 p.f.u, of BHV-4 in 50 ttl in the presence or absence of 5% rabbit complement (Serotec). Mixtures were incubated in duplicate in 96-well plates for 2 h at 37 °C or overnight at 37 °C to increase the sensitivity of the test (Bitsch, 1978) , and then 1.3 x 104 MDBK cells were added per well. After 6 days, plates were fixed and stained with an aqueous alcoholic solution of crystal violet. When the c.p.e, was complete, pairs of MAbs were considered non-neutralizing. Neutralization was considered complete when no c.p.e, was observed and partial when the cell monolayer was lysed only partially after 6 days. For measurement of the neutralizing titres, twofold dilutions of MAbs were mixed with 25 p.f.u, of clarified virus (1000 g for 15 min) or semi-purified virus (100000 gfor 90 min through a 30% sucrose cushion) and, after overnight incubation, the plates were overlaid with medium containing carboxymethyl cellulose. The neutralizing titre is the reciprocal of the highest dilution of antibodies giving at least 50% reduction in plaque number relative to the control MAb which was raised against bovine rotavirus.
Measurement of neutralizing activity before or after virus attachment.
Confluent MDBK cells grown in six-well plates (Gibco) were inoculated with 200 p.f.u, of BHV-4 per well and incubated for 2 h at 4 °C. Infected cells were washed and incubated for 6 h at 4 °C with pairs of MAbs involved in neutralization (125 Ixg of each MAb in a final volume of 500 ~tl). Simultaneously, the same pairs of MAbs (125 ktg of each MAb) were mixed with an equal volume (250 ILl) of culture medium containing 200 p.f.u, of BHV-4. After 6 h at 4 °C, the mixtures were added to confluent MDBK cells grown in six-well plates and incubated for 2 h at 4 °C at which time the plates were rinsed with culture medium. All the six-well plates were then overlaid with 0.6% carboxymethyl cellulose, incubated at 37 °C for 7 days and finally the cells were fixed and stained as described previously. The numbers of plaques were estimated and compared to the anti-bovine rotavirus MAb~ontrol virus combination.
Effect on plaque development of MAbs involved in BHV-4 neutralization.
Confluent MDBK cells grown in 24-well plates were infected with 50 p.f.u, of BHV-4 per well and incubated for 2 h at 37 °C. Wells were washed with culture medium and overlaid with MEM containing pairs of MAbs involved in neutralization (166 Ixg of each MAb per ml) and 0.6% carboxymethyl cellulose. Plates were fixed and stained after 8 days at 37 °C. The control-infected wells contained a MAb to bovine rotavirus. The mean plaque sizes were measured and compared by oneway analysis of variance and Duncan's test as described previously (Dubuisson et al., 1988) after modification of the data to obtain a normal distribution.
Competitive binding assay. MAbs were used in reciprocal competitive ELISA to determine the antigenic areas that are targets for neutralization of BHV-4 glycoproteins. Reciprocal assays were used to eliminate the effects of antibody avidity on the results. BHV-4 was prepared by infecting GBK cells, grown in 96-well plates, at a multiplicity of infection of 1 p.f.u, per cell. After 2 days, plates were fixed in acetone : distilled water (95 : 5, v/v) for 30 min at -20 °C. Plates were blocked with 1% ovalbumin in PBS-0.02% Tween 80 for 1 h at room temperature. The competing purified MAb was added in serial 10-fotd dilutions to antigen-coated wells and allowed to react for 2 h at room temperature. The wells were washed and a second biotinylated MAb was added at a predetermined optimal concentration and incubated for 1 h at room temperature. This was followed by incubation with streptavidin-horseradish peroxidase (Amersham) and substrate following the procedure recommended by the manufacturer. The percentage of competition was calculated as described by KimuraKuroda & Yasui (1983) , using the formula [100(A -n)]/(A -B), where A is the absorbance at 492 nm (A492) in the absence of competitive antibody, B is A492 in the presence of homologous antibody, and n is A,,92 in the presence of competitor. For interpretation of the results, < 20% competition was considered as non-competitive, > 20% and <80% was considered as partially competitive, and >80% was considered as fully competitive.
Results

MAbs
Twenty-three MAbs were obtained following a single-hit intrasplenic immunization 4 days before fusion; all of them were directed against the 150K/120K/51K glycoprotein as determined by immunoprecipitation and Western blotting (data not shown).
Neutralization
None of the MAbs previously produced or obtained after intrasplenic immunization neutralized in the presence or the absence of complement. Pairs of MAbs raised against the two major glycoproteins 150K/120K/51K (MAbs 1, 8, 10, 12, 13, 17, 24, 25, 26, 27, 28, 30, 31, 35, 36, 37 and 38)and 120K/16.5K (MAbs 2, 4, 7, 9, 11, 16, 18, 19, 20, 23, 29, 32 and 33) were used in neutralization tests, the mixtures being incubated overnight to increase the sensitivity of the test. Results are shown in 8, 10, 12, 13, 17, 24, 25, 26, 27, 28, 30, 31, 35, 36, 37 and 38) and 120K/16, 5K (MAbs 2, 4, 7, 9, 11, 16, 18, 19, 20, 23, 29, 32 and 33) Reciprocal competition between antibodies recognizing the antigenic areas is shown by intersection of circles. Numbers inside the circles identify the MAb recognizing the epitope. The neutralizing activity of MAbs was determined in a neutralizing test using pairs of MAbs as presented in Fig. 1 (+ represents total neutralization; + / -, partial neutralization; -, absence of neutralization; ND, not determined).
Measurement of neutralizing titres
Pairs of MAbs exhibited titres which ranged from 4 to 32, and none except MAb16 were neutralizing on their own. These titres were compared with those of a polyvalent antiserum to BHV-4 and a monospecific antiserum to the 150K/120K/51K g|ycoprotein. The neutralizing titres of antisera to BHV-4 and to the 150K/120K/51K protein were lower than those obtained with MAbs. Moreover, the neutralizing titre of a mixture of five MAbs raised against the five domains involved in neutralization ( Fig. 2 and 3) was not higher than those of pairs of MAbs. Neutralizing titres were very similar when semi-purified virus was used.
Measurement of neutralizing activity before or after viral attachment
Assays for the neutralizing activity of pairs of MAbs before or after BHV-4 attachment to cells were performed at 4°C to prevent virus uptake. Residual infectivity was greater than 100~o for all of the pairs except two (10 and 30, and 20 and 38) when added after BHV-4 attachment. Residual infectivity was lower than 100~ for all of the pairs but two (10 and 30 and 23 and 38) when added to BHV-4 before attachment. The maximum decrease of infectivity, which ranged from 25 ~ to 30 ~, was obtained for pairs 16 and 30, 16 and 33, 20 and 30, and 16 and 29 .
Effect of MAbs involved in BHV-4 neutralization on plaque development
Square roots of the data were used to obtain a normal distribution. One-way analysis of variance showed that plaque sizes were significantly different (P< 0.001). Duncan's test allowed the classification of the mean plaque sizes into six groups. Plaques obtained under culture medium containing pairs of MAbs involved in neutralization were greater than those of the control.
Competitive binding assays
MAbs used in this experiment are presented in Table 1 . Competitive binding assays were used to analyse the topography of neutralization epitopes. Each antibody was tested both for its ability to compete for binding with other antibodies directed against the same protein and for its susceptibility to competition. Areas defined by this method were subdivided if the antibodies recognizing them could be differentiated by the presence or absence of competition with antibodies from other antigenic areas on the same glycoprotein. The results of competitive binding assays are shown in Tables 2 and 3 , and a schematic representation of data is given in Fig. 2 and 3 . Several competition reactions were not reciprocal. For example, MAbs 24 and 38 competed with MAb 30 but not vice versa (Table 3 ). The same was true for MAbs 31 and 25 (Table 3) . This was not due to large differences in antibody avidities between competing antibodies because it was observed for antibodies showing similar avidities (Table 1) but it could be due to the induction of conformational changes in the second epitope after attachment of the first one.
Six epitopes on the 120K/16-5K glycoprotein were defined and grouped into two antigenic domains (I and II) (Fig. 2) . Results presented in Table 2 demonstrate that blocking between MAbs 16, 20 and 23 was complete and symmetrical but the degree of competition with the remaining MAbs was different. On the basis of these results, the targets of MAbs 16, 20 and 23 are probably overlapping or closely adjacent epitopes (epitopes Ia, Ib and Ic) which probably belong to the same antigenic domain (Fig. 2) . Similarly, MAbs 29 and 33 blocked each other totally and symmetrically, and were considered to be directed against overlapping or closely adjacent (Dubuisson et al., 1989b) .
t Determined by immunodiffusion (Dubuisson et al., 1989a) . ~: Determined by parallel titrations in an ELISA test using a single BHV-4 preparation as antigen (Dubuisson et al., 1989b) . The relative avidities were classified as low (A492<0.75), intermediate (0-75 < A492 < 1.00) and high (A492 > 1.00).
§ The neutralizing activity of the MAbs was determined in a neutralization test using pairs of MAbs as presented in Fig. 1 . +, Total neutralization; +/-, partial neutralization; -, no neutralizing activity.
11ND; not determined. (Fig. 2) . (Dubuisson et al., 1989b) . t See footnotes to Table 2 . :~ See footnotes to Table 2 . § Competition < -20%.
Similarly, MAb 19 competed partially and symmetrically with MAb 23, suggesting that the two antigenic domains identified on the 120K/16.5K glycoprotein are adjacent. Eleven epitopes on the 150K/120K/51K glycoprotein were defined and were grouped into five antigenic domains (Fig. 3) . Table 3 demonstrates that blocking between MAbs 15, 25 and 35 which are probably directed against overlapping or closely adjacent epitopes (Ia, Ib, Ic) was complete and symmetrical. In contrast, the degree of competition of these MAbs with the remaining MAbs was not symmetrical. MAb 31 competed with MAbs 15 and 35, but only partially when it was used as a competitor for MAbs 15 and 35, and not at all with MAb 25 (Table 3) . Thus the epitope identified by MAb31 was considered to be closely adjacent to those recognized by MAbs 15 and 35, and epitopes identified by MAbs 15, 25, 35 and 31 appear to belong to the same antigenic domain (Fig. 3) . Similarly, epitopes identified by MAbs 27, 28 and 10 (IVa, IVb and IVc) and those identified by MAbs 24 and 38 (IIIa and IIIb) were considered to belong to two other antigenic domains (Fig. 3) . MAb 30 competed partially with MAb 35 suggesting that the epitope recognized by this MAb was adjacent to the domain I identified on glycoprotein 150K/120K/51K. MAb 26 did not show any reciprocal competition with the other MAbs raised against 150K/120K/51K suggesting that the epitope identified by this MAb is located on another antigenic domain (V). MAbs 24, 38 and 26 showed an increase of binding when MAb 35 was used as a competitor.
Discussion
MAbs raised against BHV-4 glycoproteins were produced previously to identify the major BHV-4 structural proteins exposed to the immune system (Dubuisson et al., 1989a, b) . Two major glycoproteins were identified (150K/120K/51K and 120K/16.5K) and MAbs raised against these proteins were used in this work to study their neutralizing activity against BHV-4. Moreover MAbs involved in neutralization were studied to identify the step in the infectious cycle that they block and to locate their target epitopes on the 150K/120K/51K and 120K/16-5K glycoproteins.
None of the anti-BHV-4 MAbs except for MAb 16 could neutralize virus alone in the absence or presence of complement. When pairs of MAbs are used in neutralization tests some of them exhibit a partial or a total neutralizing activity. Synergistic neutralization by pairs of MAbs recognizing viral glycoproteins has been described for other viruses, such as vesicular stomatitis virus (Volk et al., 1982) , La Crosse virus (Kingsford, 1984) , Newcastle disease virus (Russell, 1986 ) and respiratory syncytial virus (Anderson et al., 1988) . Kingsford (1984) showed that many of the antibody pairs that enhanced neutralization were also synergistic in competitive binding assays supporting the idea that an increase of avidity between the glycoprotein and the two antibody molecules can result in a greater proportion of bound antibody and, thus, a greater degree of neutral-ization. In this work, synergistic binding of pairs of MAbs to viral glycoproteins was observed in competitive binding assays but only for MAbs not involved in neutralization and some pairs included MAbs which were specific for the two glycoproteins (150K/120K/51K and 120K/16.5K) as already described by Anderson et al. (1988) for respiratory syncytial virus. This would suggest that the synergistic neutralization was not due to an increase of the amount of neutralizing antibodies bound to the virus as proposed by Kingsford (1984) for La Crosse virus. Alternative explanations could be that the two anti-BHV-4 MAbs bind around a glycoprotein domain involved in viral attachment or fusion, as these are the main functions blocked by neutralizing antibodies to enveloped viruses (Dietzschold et al., 1987; Fuller & Spear, 1987; Muller & Hutt-Fletcher, 1988) , or that a conformational change takes place in the glycoprotein after binding of the second antibody as suggested in some cases for La Crosse virus (Kingsford, 1984) .
Neutralizing titres obtained with purified virus were similar to those observed with clarified virus. Therefore, the presence of soluble proteins, as described for herpes simplex virus type 1 (HSV-1) (Randall et al., 1980) , cannot account for the weak neutralization observed with BHV-4.
If the mechanism of neutralization involves primarily the inhibition of virus attachment, adsorbed virions should be resistant to neutralization. In contrast, if the mechanism involves the blocking of some step subsequent to virus adsorption, these antibodies should neutralize cell surface-bound virions as shown for HSV (Fuller & Spear, 1987) and rabies virus (Dietzschold et al., 1987) . The 150K/120K/51K and 120K/16.5K glycoproteins appear to be involved in BHV-4 attachment. Indeed, most of the pairs of MAbs did not induce a decrease in viral infectivity when they were added to the virus after attachment to the cells and a significant but low (~< 30~) decrease of infectivity was observed when MAb pairs were added to the virus before attachment.
Plaque sizes obtained in medium containing pairs of MAbs were larger than for the control. These results show that pairs of MAbs do not neutralize BHV-4 infectivity by inhibiting enlargement of plaques as is the case for some MAbs raised against gB (Highlander et al., 1988) , gD (Minson et al., 1986) or gH (Buckmaster et al., 1984) of HSV. These results also suggest that neutralizing antibodies to BHV-4 had an antagonistic effect which increased virus propagation. The fusogenic domains of BHV-4 glycoproteins could be better exposed to the cell membrane after antibody binding to adsorbed virus or after binding to glycoprotein present on the surface of infected cells.
Six epitopes were identified on the 120K/16.5K glycoprotein and they were located in two antigenic domains as indicated by the competition tests. (Dubuisson et al., 1989a) confirming that they are directed against distinct epitopes. Results of Western blotting did not allow us to determine the subunit identified by these six MAbs except for MAb 20 which recognized the 16-5K polypeptide (Dubuisson et al., 1989b) . Eleven epitopes were identified on the 150K/ 120K/51K glycoprotein and they were located in five antigenic domains according to competition tests. The 120K and 51K subunits were recognized by six (10, 24, 27, 28, 30 and 38) and four (15, 25, 31 and 35) MAbs respectively (Dubuisson et al., 1989b) . The 120K protein was identified by MAbs involved in the neutralization of BHV-4 and three neutralizing domains were identified. MAbs raised against this 120K subunit have also been tested against various BHV-4 isolates and showed different patterns of recognition of these isolates, confirming that they are directed against distinct epitopes (Dubuisson et al., 1989b) . Thus, the 120K polypeptide seems to be the major subunit of the 150K/120K/51K glycoprotein which induces neutralizing antibodies. Epitopes located on the 51K subunit were not or, only very weakly, involved in BHV-4 neutralization. Moreover, MAbs raised against the epitopes of the 51K subunit recognized the majority of the BHV-4 isolates (Dubuisson et al., 1989a) and showed a high avidity, suggesting that 51K is highly immunogenic and that domain I of the 150K/120K/51K glycoprotein is highly conserved between BHV-4 strains.
Epitopes that were involved in neutralization and located on the 150K/120K/51K and the 120K/16-5K glycoproteins are conformational (Dubuisson et al., 1989b) and MAbs raised against them do not recognize the majority of BHV-4 isolates (Dubuisson et al., 1989a) . This suggests that the antigenic domains which are the targets of these MAbs could be subject to the selective pressure of the immune system. The weak avidity of the neutralizing MAbs suggests that the antigenic domains are not easily accessible.
In conclusion, MAbs directed to BHV-4 glycoproteins possess only a weak neutralizing activity and a low avidity. These results suggest that glycoprotein domains involved in BHV-4 infectivity are poorly exposed to the immune system.
